Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain

Journal of Controlled Release

Volumn 59, Issue 3, 1999, Pages 299-307

  Yang, Shi Cheng ^a,b   Lu, Li Fang ^b   Cai, Ying ^c   Zhu, Jia Bi ^b   Liang, Bing Wen ^c   Yang, Chang Zheng ^a  

^a NANJING UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c No 454 Hospital of PLA   (China)

Author keywords

Body distribution; Camptothecin; Drug targeting; Solid lipid nanoparticles; Sustained release system

Indexed keywords

CAMPTOTHECIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION; ZETA POTENTIAL;

ANIMALS; BRAIN CHEMISTRY; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; INFUSIONS, INTRAVENOUS; LIPIDS; MICE; MICE, INBRED C57BL; PARTICLE SIZE; POLOXAMER; TISSUE DISTRIBUTION;

EID: 0032950389     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00007-3     Document Type: Article

References (30)

1. R.H. Müller, W. Mehnert, J.S. Lucks, C. Schwarz, A. zur Mühlen, H. Weyhers, C. Freitas, D. Rühl, Solid lipid nanopaticles (SLN) - an alternative colloidal carrier system for controlled drug delivery, Eur. J. Pharm. Biopharm. 41 (1995) 62-69.
2. C. Schwarz, W. Mehnert, J.S. Lucks, R.H. Müller, Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization, J. Control. Release 30 (1994) 83-96.
3. H. Heiati, N.C. Phillips, R. Tawashi, Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride, Pharm. Res. 13 (1996) 1406-1410.
4. K. Westesen, H. Bunjes, M.H.J. Koch, Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential, J. Control. Release 48 (1997) 223-236.
5. R.H. Müller, S. Maassen, C. Schwarz, W. Mehnert, Solid lipid nanopaticles (SLN) as potential carrier for human use: interaction with human granulocytes, J. Control. Release 47 (1997) 261-269.
6. R.H. Müller, S. Maassen, H. Weyhers, W. Mehnert, Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407, J. Drug Target 4 (1996) 161-170.
7. P. Couvreur, C. Dubernet, F. Puisieux, Controlled drug delivery with nanoparticles: Current possibilities and future trend, Eur. J. Pharm. Biopharm. 41 (1995) 2-13.
8. M.E. Wall, M.C. Wani, C.E. Cook, K.H. Palmer, A.T. McPhail, G.A. Sim, Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from camptotheca acuminata, J. Am. Chem. Soc. 88 (1966) 3888-3890.
9. C. Jaxel, K.W. Kohn, M.C. Wani, M.E. Wall, Y. Pommier, Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and for a relation to antitumour activity, Cancer Res. 49 (1989) 1465-1469.
10. M. Potmesil, Camptothecins: from bench research to hospital wards, Cancer Res. 54 (1994) 1431-1439.
11. B.C. Giovanella, H.R. Hinz, A.J. Kozielski, J.S. Stehlin Jr., R. Silber, M. Potmesil, Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin, Cancer Res. 51 (1991) 3052-3055.
12. B.C. Giovanella, J.S. Stehlin, M.E. Wall, M.C. Wani, A.W. Nicholas, L.F. Liu, R. Silber, M. Potmesil, DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts, Science 246 (1989) 1046-1048.
13. T.G. Burke, Z. Mi, The structural basis of camptothecin interactions with human serum albumin impact on drug stability, J. Med. Chem. 37 (1994) 40-46.
14. E. Merisko-Liversidge, P. Sarpotdar, J. Bruno, S. Hajj, L. Wei, N. Peltier, J. Rake, J.M. Shaw, S. Pugh, L. Polin, J. Jones, T. Corbett, E. Cooper, G.G. Liversidge, Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs, Pharm. Res. 13 (1996) 272-278.
15. J.-P. Lon, A.E. Ahmed, Determination of camptothecin in biological fluids using reversed-phase high-performance liquid chromatography with fluorescence detection, J. Chromatogr. Biomed. Appl. 530 (1990) 367-376.
16. J.H. Beijnen, High-performance liquid chromatographic analysis of the antitumour drug camptothecin and its lactone ring-opened form in rat plasma, J. Chromatogr. Biomed. Appl. 617 (1993) 111-117.
17. A. Shenderova, T.G. Burke, S.P. Schwendeman, Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles, Pharm. Res. 14 (1997) 1406-1414.
18. A. Kurihara, Y. Shibayama, A. Mizota, A. Yasuno, M. Ikeda, K. Sasagawa, T. Kobayashi, M. Hisaoka, Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice, Pharm. Res. 13 (1996) 305-310.
19. Z. Mi, T.G. Burke, Differential interactions of camptothecin lactone and carboxylated forms with human blood components, Biochemistry 33 (1994) 10325-10336.
20. A. Sánchez, M.J. Alonso, Poly(D,L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected cyclosporin A, Eur. J. Pharm. Biopharm. 41 (1995) 31-37.
21. L. Illum, P. West, C. Washington, S.S. Davis, The effect of stabilising agents on the organ distribution of lipid emulsions, Int. J. Pharm. 54 (1989) 41-49.
22. L. Illum, S.S. Davis, R.H. Müller, E. Mak, P. West, The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer-Poloxamine 908, Life Sci. 40 (1987) 367-374.
23. L. Illum, S.S. Davis, Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration, J. Pharm. Sci. 72 (1983) 1086-1089.
24. R. Löbenberg, L. Araujo, H. Von Briesen, E. Rodgers, J. Kreuter, Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats, J. Control. Release 50 (1998) 21-30.
25. S.M. Moghimi, Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers, Adv. Drug Deliv. Rev. 16 (1995) 183-193.
26. 2 analogue, J. Pharm. Pharmacol. 48 (1996) 1016-1022.
27. J. Kreuter, R.N. Alyautdin, D.A. Kharkevich, A.A. Ivanov, Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles), Brain Res. 674 (1995) 171-174.
28. R.N. Alyautdin, V.E. Petrov, K. Langer, A. Berthold, D.A. Kharkevich, J. Kreuter, Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles, Pharm. Res. 14 (1997) 325-328.
29. R. Alyautdin, D. Gothier, V. Petrov, D. Kharkevich, J. Kreuter, Analgesic activity of hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles, Eur. J. Pharm. Biopharm. 41 (1995) 44-48.
30. A. Gabr, A. Kuin, M. Aalders, H. El-Gawly, L.A. Smets, Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH, Cancer Res. 57 (1997) 4811-4816.